The Lancet

Open in Telegram

All the latest articles published on Lancet Journal Discussion Group https://t.me/Medical_Professionals_Forum Contact us https://t.me/Contact_Updates_in_Medicine_Bot

USA2 159 Medicine1 322...

📈 Analytical overview of Telegram channel The Lancet

Channel The Lancet (@the_lancet) in the English language segment is an active participant. Currently, the community unites 17 744 subscribers, ranking 1 322 in the Medicine category and 2 159 in the USA region.

📊 Audience metrics and dynamics

Since its creation on невідомо, the project has demonstrated rapid growth, gathering an audience of 17 744 subscribers.

According to the latest data from 07 September, 2026, the channel demonstrates stable activity. Although there has been a change in the number of participants by 206 over the last 30 days and by 0 over the last 24 hours, overall reach remains high.

Verification status: Not verified
Engagement rate (ER): The average audience engagement rate is 4.17%. Within the first 24 hours after publication, content typically collects 2.03% reactions from the total number of subscribers.
Post reach: On average, each post receives 740 views. Within the first day, a publication typically gains 361 views.
Reactions and interaction: The audience actively supports content: the average number of reactions per post is 1.
Thematic interests: Content is focused on key topics such as cancer, patient, treatment, disease, vaccine.

📝 Description and content policy

The author describes the resource as a platform for expressing subjective opinions:
“All the latest articles published on Lancet Journal Discussion Group https://t.me/Medical_Professionals_Forum Contact us https://t.me/Contact_Updates_in_Medicine_Bot”

Thanks to the high frequency of updates (latest data received on 08 September, 2026), the channel maintains relevance and a high level of publication reach. Analytics show that the audience actively interacts with content, making it an important point of influence in the Medicine category.

17 744

Subscribers

No data24 hours

+267 days

+20630 days

740

Post views

~ 36124 hours

~ 46048 hours

4.17%

Engagement rate

~ 3

Posts per day

Ads index

beta

Posts Archive

17 745

[Articles] Use of the bacterial lysate OM-85 for the primary prevention of wheezing lower respiratory illness in preschool children: a randomised, placebo-controlled trial https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)01443-1/fulltext?rss=yes Oral administration of OM-85 in early life did not decrease the incidence of wheezing lower respiratory tract illness in this high-risk population. Bacterial lysates are not efficacious for the primary prevention of asthma-like symptoms during the preschool years.

17 745

[Comment] Early-life primary prevention of childhood asthma https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)01769-1/fulltext?rss=yes Asthma-related symptoms, such as wheezing, are highly prevalent among preschool children. Asthma is a complex disease and originates from genetic susceptibility combined with different environmental exposures. Early life is a specific critical period for development of later-life asthma.1 Population studies have identified various fetal and early-childhood risk factors for asthma, including early-life respiratory tract infections.1 Early-life respiratory tract infections have not only short-term consequences, but seem also to affect the development of both the respiratory and immune systems, and subsequently predispose individuals to chronic respiratory diseases in later life.

17 745

[Comment] Can wealth redistribution offset the collapse of aid? https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)01814-3/fulltext?rss=yes Official development assistance (ODA) is being cut faster than at any point in history.1 The USA, the UK, Japan, Germany, France, and the Netherlands have all reduced aid between 2024 and 2025, and forecasts point to further large declines up to and after 2026.1 These cuts are occurring within the backdrop of extreme and rising wealth concentration: the richest 10% of the world's population own 75% of global personal wealth, whereas the poorest 50% own just 2%.2 Considering this fact, in The Lancet Gonzalo Barreix Sibils and colleagues ask a largely unexamined question: could redistributing even a small share of that wealth offset the health damage caused by the humanitarian and development aid crisis?3

17 745

[Articles] Wealth redistribution policies to mitigate the impact of development assistance defunding: a retrospective evaluation and forecasting analysis up to 2030 https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)00975-X/fulltext?rss=yes The implementation of wealth redistribution policies proposed in recent high-level international agreements could mitigate the health consequences of the current ODA defunding crisis, avert millions of deaths, and support the achievement of the UN Sustainable Development Goals, particularly those related to health.

17 745

[Articles] Induction and consolidation atezolizumab with stereotactic body radiation therapy versus radiation alone in high-risk, early-stage non-small-cell lung cancer (SWOG/NRG S1914): a multicentre, open-label, superiority, phase 3, randomised controlled trial https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)01655-7/fulltext?rss=yes In the first fully reported phase 3 cooperative group trial to assess immunotherapy in inoperable early-stage NSCLC, we observed no improvement in overall survival with atezolizumab plus SBRT, and more grade 3 or higher adverse events were reported with atezolizumab combined with SBRT.

17 745

[Series] The changing therapeutic landscape of small-cell lung cancer https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)01244-4/fulltext?rss=yes Small-cell lung cancer (SCLC) is an exceptionally aggressive malignancy: highly proliferative, heterogeneous, and frequently metastatic at diagnosis. Although initially responsive to chemotherapy, such responses are typically transient, and recurrent disease has been largely refractory to standard cytotoxics. The past decade has been notable for major advances in our understanding of SCLC biology, and this preclinical progress is now informing multiple novel therapeutic approaches for this disease.

17 745

[Review] Patient-centred and fit-for-purpose clinical trials in rare cancers: lessons from sarcomas for operationalising 2024 WHO Guidance and ICH E6(R3) https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(26)00445-1/fulltext?rss=yes Rare cancers account for approximately one quarter of cancer diagnoses in Europe, yet prevailing clinical trial governance frameworks were developed for common malignancies and conventional randomised designs. The 2024 WHO Guidance for best practices for clinical trials and ICH E6(R3) reframe trial quality around scientific validity, ethical proportionality, feasibility, equity, and meaningful patient engagement — principles that are structurally tested by rare cancer research. This narrative review examines how these principles are operationalised in representative sarcoma trials, where biological heterogeneity, low incidence, and international collaboration expose the limits of standard approaches.

17 745

[Articles] Steroid, thiamine, and ascorbic acid for comatose out-of-hospital cardiac arrest survivors (STAR): a randomised, placebo-controlled, phase 2 trial https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(26)00444-X/fulltext?rss=yes Early administration of hydrocortisone, ascorbic acid, and thiamine did not reduce neuronal injury or improve 6-month clinical outcomes. The findings do not support empiric neuroprotective use in comatose OHCA survivors.

17 745

[Comment] High-quality mentorship can improve physician-scientist recruitment, retention, and career satisfaction https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)01707-1/fulltext?rss=yes Physician-scientists, who engage in both patient care and scientific inquiry, represent an increasingly small portion of the physician workforce. In the USA, only 1·3% of physicians reported research as their major professional activity in 2020.1 In the UK, clinical academics represented just 3·2% of the consultant workforce in 2025.2

17 745

[Correspondence] Gold standard vaccine policy as a global health signal https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)01698-3/fulltext?rss=yes The US Executive Order of Aug 10, 2026, establishing “Gold Standard Childhood Vaccine Recommendations”,1 should be considered not only a domestic policy change but also a potential global health signal. By redefining what childhood vaccines should be routinely recommended, encouraging separation of the combined measles, mumps, and rubella vaccine, and advocating separate medical visits for different childhood immunisations, the policy risks conflating parental choice with the optimisation of evidence-based vaccination delivery.

17 745

[Correspondence] Integrating responders’ mental health into the Ebola outbreak response https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)01738-1/fulltext?rss=yes Ebola outbreaks place extraordinary demands on the people tasked with containing them. The ongoing Bundibugyo virus disease outbreak in the Democratic Republic of the Congo, following cross-border transmission to Uganda, is occurring amid armed conflict, population displacement, humanitarian pressures, sustained transmission, and infections and deaths among health-care workers, underscoring that outbreak control depends on a diverse workforce operating under exceptional pressure.1 Responders face infection risk, repeated exposure to severe illness and death, fear of transmitting infection to their families, long working hours, exhaustion, isolation, stigma, and sometimes hostility.

17 745

[Articles] Efficacy and safety of tiotropium in partial and uncontrolled preschool asthma (TIPP): a phase III, multicentre, randomised, double-blind, placebo-controlled trial https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(26)00425-6/fulltext?rss=yes Tiotropium did not reduce the risk of a severe asthma exacerbation, but was well tolerated as add-on therapy to ICS in preschool children with high-risk asthma.

17 745

[Articles] Natural language processing-based model to predict radiation pneumonitis in patients with locally advanced non-small cell lung cancer undergoing chemoradiotherapy: a retrospective cohort study https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(26)00390-1/fulltext?rss=yes In this early work, NLP-based extraction of longitudinal symptoms from routine clinical documentation meaningfully enhances RP prediction in patients undergoing CRT for NSCLC. This approach leverages existing electronic health record infrastructure to deliver real-time, scalable, and interpretable risk estimates, offering a pathway toward potential early intervention and personalized toxicity management. The model and DCA requires external and prospective validation before clinical deployment; as such, future work should focus on this validation and integration into clinical decision support systems.

17 745

[Comment] Late-onset seizures as a sentinel of Alzheimer's disease progression in Down syndrome https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)00959-1/fulltext?rss=yes Epilepsy is a common co-occurring condition in older adults with Down syndrome and frequently associated with the emergence of Alzheimer's disease-related cognitive decline.1 Likely to be under-recognised and often untreated in the earlier stages, late-onset myoclonic epilepsy in Down syndrome (LOMEDS) presents as myoclonic or tonic–clonic seizures and can be both a manifestation of underlying Alzheimer's disease pathology and an accelerator of disease progression.2 How seizure onset timing in adults with Down syndrome relates to Alzheimer's disease symptoms and progression remains unclear, complicating interpretation of decline and clinical management.

17 745

[Comment] Closing the preparedness gap: moving beyond emergency response to sustain the medical countermeasure ecosystem https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)01768-X/fulltext?rss=yes Infectious disease outbreaks expose weaknesses that are overlooked between crises. The ongoing Ebola virus disease outbreak caused by Bundibugyo virus (Orthoebolavirus bundibugyoense; BDBV) in the Democratic Republic of the Congo, during which there has been cross-border transmission into Uganda, has brought together governments, regional and multilateral organisations, manufacturers, research institutions, and financing partners. These actors are accelerating the development, evaluation, and deployment of medical countermeasures (MCMs), including diagnostics, vaccines, therapeutics, and personal protective equipment (PPE).

17 745

[Comment] Kidney xenotransplantation—bridge to allotransplantation or destination treatment? https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)01479-0/fulltext?rss=yes The shortage of human kidneys remains a central problem in transplantation, and many candidates die or are removed from the waiting list before an organ becomes available.1 Genetically engineered porcine kidneys have long been proposed to expand the donor pool,2 and over the past 3 years the field has rapidly moved from preclinical models to decedent models to living recipients.3–5 In their Article, Leonardo Riella and colleagues report a porcine kidney xenograft that supported a living human recipient for 271 days—the longest dialysis-free xenograft function described to date—followed by explantation and a subsequent deceased-donor human kidney transplantation.

17 745

[Articles] Natural history and clinical impact of epilepsy in adults with Down syndrome: a multicentre clinical study https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)00980-3/fulltext?rss=yes Epilepsy increases sharply after symptomatic Alzheimer's disease onset in people with Down syndrome. The association of epilepsy with reduced survival and accelerated cognitive decline underscores the need for targeted preventive and therapeutic strategies against Alzheimer's disease-related epileptogenesis and hyperexcitability.

17 745

[Articles] Porcine kidney xenotransplantation as a bridge to allotransplantation: a first-in-human study https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)01295-X/fulltext?rss=yes This case shows that porcine kidney xenotransplantation can provide prolonged renal support and be discontinued without clinically significant allosensitisation or zoonotic infection. Early cellular rejection resolved with treatment, whereas later graft failure was associated with microvascular injury progressing to thrombotic microangiopathy despite a negative donor-specific crossmatch, supporting the possibility that mechanisms beyond conventional antibody-mediated rejection contributed to late graft injury.

17 745

[Articles] Bundibugyo virus disease evidence map: a rapid research needs appraisal https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(26)00432-3/fulltext?rss=yes Whilst acknowledging the limitations of such a rapid appraisal, our findings show that urgent, coordinated investment is needed in countermeasure trials inclusive of pregnant women and children, supported by observational studies community engagement and co-production.

17 745

[Articles] Long-acting HIV pre-exposure prophylaxis adherence and discontinuation: a global systematic review and meta-analysis https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(26)00442-6/fulltext?rss=yes Adherence to LAI-PrEP remained high through 12 months, with the best adherence being observed in clinical trials, which serve as upper-bound benchmarks. Compared to LAI-PrEP, IVR-PrEP had lower adherence and higher discontinuation. Efforts facilitating longer-term adherence warrant research.